Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

In a report released yesterday, C J Muse from Cantor Fitzgerald maintained a Hold rating on KLA (KLAC – Research Report), with a price target of $875.00. The company’s shares closed yesterday ...

Meanwhile, his firm, Cantor Fitzgerald has a significant presence in Ireland, with offices in Cork, Dublin and Limerick Howard Lutnick, chairman and chief executive officer of Cantor Fitzgerald ...

Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is confident that Cigna can correct their stop-loss pricing ...

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested under $70 as “close your eyes” level for Lam over the ...

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $160.00 target price on the stock. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.13 per share.

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

On Wednesday, Cantor Fitzgerald initiated coverage on Galaxy Digital Holdings Ltd (TSX:GLXY:CN) (OTC: BRPHF), assigning an Overweight rating to the company's stock with a price target of Cdn$44.00.

Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (WBAG:LRC2) from Neutral to Overweight. There are 1,883 funds or institutions reporting positions ...